# Who does Celltrion pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/celltrion · Facet: suppliers · Updated: 2026-07-12T04:19:32.885+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Celltrion's confirmed suppliers/cost counterparties include 애브비 plus 2 undisclosed/aggregate relationships. Per the valuechain.wiki graph: 3 cost edges, backed by 1 dated sources, 1 of them primary filings (as of 2026-07-12).

### 세포배양 배지·바이오의약품 원재료 공급망 (high)
- metric: Amount 345,744 KRW_mn · FY2025 · Consolidated raw-material purchases (biopharma, 68.42% of total)
- note: Largest FY2025 purchase category. Biopharma raw materials (cell-culture media etc.) KRW 345.7bn (68.42% of purchases) plus sub-materials (CIP 100 etc.) KRW 49.2bn. Sourced build-to-order; key suppliers undisclosed for competitive/contractual reasons.
- [confirms] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "Biopharma raw material 'media etc.' KRW 345,744mn (68.42%); key suppliers are not disclosed for competitive and contractual reasons."

### 케미컬의약품 원료 공급망 (오로트산카르니틴 등) (high)
- metric: Amount 110,421 KRW_mn · FY2025 · Consolidated raw-material purchases (chemical drugs, 21.85% of total)
- note: FY2025 chemical-drug raw materials (orotic acid carnitine etc.) KRW 110.4bn (21.85% of purchases) for Celltrion Pharm Cheongju small-molecule production. Suppliers undisclosed.
- [confirms] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "Chemical-drug raw material 'orotic acid carnitine etc.' KRW 110,421mn (21.85%). Total purchases KRW 505,338mn."

### Kaigene, Inc. (희귀 자가면역 신약 라이선스-인) (mid)
- metric: contract 8 USD_mn · 2025-11-04~ · License-in upfront $8M (dev up to $111M, sales up to $625M, royalty 5-10%)
- note: On 2025-11-04 Celltrion signed a license-in deal with US-based Kaigene for a rare autoimmune drug candidate: $8M upfront (~KRW 11.4bn), up to $111M development milestones, up to $625M sales milestones (at $4bn net sales), and 5-10% royalties. Part of its push into next-gen modalities (ADC, bispecifics).
- [confirms] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "License-in of a rare autoimmune drug candidate from Kaigene, Inc. (US): $8M upfront (~KRW 11.4bn), up to $111M development milestones, up to $625M sales milestones, royalties 5-10% of net sales."

### 애브비 (mid)  → /abbvie.md
- note: Yuflyma (CT-P17) is a biosimilar of AbbVie's originator Humira. To launch in the US in 2023, Celltrion completed a patent agreement with AbbVie (biosimilar patent settlements typically carry royalty payments). Amount undisclosed.
- [mentions] FSS DART (KO, filing, published 2026-03-16) https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260316001415: "Yuflyma, a Humira biosimilar, launched in the US in July 2023 after completing a patent agreement with the originator (AbbVie)."

Reverse side: https://valuechain.wiki/celltrion/customers.md · Ripple: https://valuechain.wiki/celltrion/ripple.md

---
Full node: https://valuechain.wiki/celltrion.md · JSON: https://valuechain.wiki/celltrion.json